Department of Medicine (Cardiology), Case Western Reserve School of Medicine, 4-533 Wolstein Research Bldg., 2103 Cornell Rd., Cleveland, OH 44106, USA.
J Mol Cell Cardiol. 2009 Jul;47(1):57-65. doi: 10.1016/j.yjmcc.2009.03.025. Epub 2009 Apr 15.
In the classical pathway, the opposing activities of guanylyl cyclases (GC) and phosphodiesterases (PDE), and the effect of the cGMP-dependent protein kinase (cGK) on its targets, determine the biological responses to NO signaling. Here we tested the hypothesis that vascular dysfunction may be due to altered expression and activity of these effectors of NO signaling. Every other set of rat second order mesenteric resistance arteries (MA) were ligated, resulting in chronic low flow (LF) in the upstream MA1 and high flow (HF) in the adjacent MA1 without tissue ischemia. eNOS and iNOS were up-regulated in HF and LF MA1, respectively, in the sub-acute phase (four days) of vascular remodeling. The Day4 HF/LF MA1s were under increased control of NO as indicated by reduced sensitivity to the vasoconstrictor phenylephrine and its normalization with the NOS antagonist L-NAME. PDE5 mRNA and protein were also significantly up-regulated in the HF/LF MA1 with no change in sGC or PKG1, an effect that was dependent upon NO synthesis. The PDE5 inhibitor Sildenafil was several-fold more powerful in relaxing the HF/LF MA1s, and pre-treatment with Sildenafil uncovered an increased responsiveness of HF/LF MA1s to the NO donor DEA/NO. We conclude that induction of PDE5 de-sensitizes this systemic resistance artery to sustained NO signaling under chronic HF/LF. Treatment with PDE5 antagonists, in contrast to NO donors, may more specifically and effectively increase blood flow to chronically hypo-perfused tissues.
在经典途径中,鸟苷酸环化酶(GC)和磷酸二酯酶(PDE)的拮抗作用,以及 cGMP 依赖性蛋白激酶(cGK)对其靶标的作用,决定了对 NO 信号的生物学反应。在这里,我们检验了这样一个假设,即血管功能障碍可能是由于这些 NO 信号转导效应物的表达和活性改变所致。每对大鼠二级肠系膜阻力动脉(MA)被结扎,导致上游 MA1 的慢性低流量(LF)和相邻 MA1 的高流量(HF),但没有组织缺血。在血管重塑的亚急性阶段(四天),HF 和 LF MA1 中的 eNOS 和 iNOS 分别上调。HF/LF MA1 对 NO 的控制增加,表现为对血管收缩剂苯肾上腺素的敏感性降低,并用 NOS 拮抗剂 L-NAME 使其正常化。HF/LF MA1 中的 PDE5 mRNA 和蛋白也显著上调,但 sGC 或 PKG1 没有变化,这种作用依赖于 NO 合成。PDE5 抑制剂西地那非在松弛 HF/LF MA1 方面更有效几倍,而且西地那非预处理揭示了 HF/LF MA1 对 NO 供体 DEA/NO 的反应性增加。我们得出结论,PDE5 的诱导使这种全身阻力动脉对慢性 HF/LF 下持续的 NO 信号脱敏。与 NO 供体相比,PDE5 拮抗剂的治疗可能更特异性和有效地增加慢性低灌注组织的血流量。